Pull to refresh
Logo
Daily Brief
Following Why Sign Up
Weight-loss pills that work like Ozempic arrive, no injection required

Weight-loss pills that work like Ozempic arrive, no injection required

New Capabilities
By Newzino Staff |

Eli Lilly's Foundayo joins Novo Nordisk's oral Wegovy in a race to replace needles with pills — and make GLP-1 treatment accessible to millions more people

Today: Eli Lilly begins shipping Foundayo via LillyDirect

Overview

For two years, the most effective weight-loss drugs on the market required a weekly injection. That barrier is now falling. Eli Lilly began shipping Foundayo — the first oral GLP-1 weight-loss pill that can be taken any time of day without food or water restrictions — on April 6, 2026, just five days after the Food and Drug Administration (FDA) approved it in a record 50-day review. Priced at $149 per month for self-pay patients and as low as $25 with commercial insurance, Foundayo undercuts the list price of injectable alternatives by roughly 85%.

Why it matters

Effective weight-loss treatment just went from weekly injections costing $1,000+ to a daily pill for $149 — opening the door to tens of millions more patients.

Key Indicators

50 days
FDA review time
Fastest new molecular entity approval since 2002, coming 294 days ahead of the scheduled review deadline
$149/mo
Self-pay price
Entry-level monthly cost without insurance, compared to $1,000+ list prices for injectable GLP-1 drugs
12.4%
Average weight loss at top dose
Mean body weight reduction at 36 mg dose over 72 weeks in patients without type 2 diabetes
$180B
Projected GLP-1 market by 2030
Estimated global market size for GLP-1 receptor agonist drugs by end of decade
30M
Projected U.S. patients by 2030
Estimated number of Americans on GLP-1 treatment by 2030, up from roughly 20 million in 2026

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Sign Up

Debate Arena

Two rounds, two personas, one winner. You set the crossfire.

People Involved

David Ricks
David Ricks
Leading Lilly's obesity drug expansion
 Lars Fruergaard Jørgensen
Lars Fruergaard Jørgensen
Defending market position against Lilly's oral entry

Organizations Involved

Eli Lilly and Company
Eli Lilly and Company
Pharmaceutical Company
Launched Foundayo, expanding oral GLP-1 market

Indianapolis-based pharmaceutical company that has become one of the two dominant players in the GLP-1 obesity drug market alongside Novo Nordisk.
Novo Nordisk
Novo Nordisk
Pharmaceutical Company
First-mover in oral GLP-1 obesity pills, now facing direct competition

Danish pharmaceutical company that pioneered GLP-1 obesity treatment with Wegovy and launched the first oral GLP-1 obesity pill in December 2025.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal Regulatory Agency
Approved Foundayo under new fast-track voucher program

The federal agency responsible for approving drugs in the United States, which reviewed Foundayo in a record 50 days under its new Commissioner's National Priority Voucher pilot program.

Timeline

  1. Eli Lilly begins shipping Foundayo via LillyDirect

    Market

    Eli Lilly starts shipping Foundayo directly to consumers through its LillyDirect platform at $149 per month for self-pay patients and $25 per month with commercial insurance, with broader retail pharmacy availability expected shortly after.

  2. FDA approves Foundayo in record 50-day review

    Regulatory

    The FDA approves Eli Lilly's Foundayo (orforglipron) as the first oral GLP-1 weight-loss pill without food or water restrictions, completing its review 294 days ahead of the scheduled deadline — the fastest new molecular entity approval since 2002.

  3. Oral Wegovy hits 50,000 weekly subscriptions in first weeks

    Market

    Novo Nordisk's oral Wegovy reaches 50,000 weekly subscriptions within its first three weeks on the market, demonstrating strong consumer demand for pill-form GLP-1 treatment.

  4. Novo Nordisk's oral Wegovy becomes first oral GLP-1 pill for obesity

    Regulatory

    The FDA approves a high-dose oral semaglutide pill (oral Wegovy) for obesity, making it the first oral GLP-1 for weight loss. The pill requires empty-stomach dosing with 30-minute restrictions on food and water.

  5. Lilly announces positive ATTAIN Phase 3 results for orforglipron

    Clinical Trial

    Eli Lilly reports that orforglipron achieved 12.4% average weight loss at the highest dose over 72 weeks in the ATTAIN-1 trial, with over half of patients losing 10% or more of their body weight.

  6. FDA launches National Priority Voucher fast-track program

    Regulatory

    The FDA announces its Commissioner's National Priority Voucher pilot program, offering review timelines of one to two months for drugs addressing national health priorities including affordability and unmet medical needs.

  7. Pfizer exits oral GLP-1 race after liver safety concerns

    Industry

    Pfizer discontinues its oral GLP-1 candidate danuglipron due to liver enzyme elevations, narrowing the near-term competitive field to Lilly and Novo Nordisk.

  8. Orforglipron Phase 2 results published in New England Journal of Medicine

    Clinical Trial

    Phase 2 trial data showing meaningful weight loss with oral orforglipron published in the New England Journal of Medicine, establishing the drug as a viable oral alternative to injectable GLP-1s.

  9. Injectable Wegovy approved, launching the GLP-1 obesity era

    Regulatory

    The FDA approves Novo Nordisk's injectable semaglutide (Wegovy) for chronic weight management, creating the first blockbuster GLP-1 obesity drug and igniting a pharmaceutical gold rush.

  10. Lilly licenses orforglipron from Chugai Pharmaceutical

    Development

    Eli Lilly acquires worldwide development and commercialization rights for orforglipron, an oral GLP-1 receptor agonist discovered by Japan's Chugai Pharmaceutical.

Scenarios

1

Oral pills replace injectables as default GLP-1 treatment within two years

Discussed by: JP Morgan analysts, Goldman Sachs pharmaceutical research, multiple endocrinologists quoted in STAT News

As Foundayo and oral Wegovy mature in the market and patients demonstrate willingness to switch from injectables, oral GLP-1s capture the majority of new prescriptions by 2028. The convenience advantage — no needles, no refrigeration, and in Foundayo's case no food restrictions — proves decisive for the tens of millions of obese adults who never started injectable treatment. Oral formulations grow from under 20% of the GLP-1 market to over 50%, though injectables retain an edge for patients needing maximum weight loss.

2

Price war drives GLP-1 costs below $100 per month, reshaping insurance coverage

Discussed by: GoodRx research analysts, health policy researchers at Brookings and Kaiser Family Foundation

Lilly's aggressive $149 self-pay pricing forces Novo Nordisk and eventual competitors to match or undercut, triggering a price war that pushes oral GLP-1 costs below $100 per month within two years. At these price points, insurers — including Medicare — find it cheaper to cover the drugs than to treat the downstream consequences of obesity (heart disease, diabetes, joint replacements). Coverage mandates follow, and GLP-1 treatment becomes as routine as statin prescriptions.

3

Convenience gap narrows as Novo Nordisk reformulates oral Wegovy

Discussed by: Novo Nordisk investor presentations, Bernstein pharmaceutical analysts

Novo Nordisk develops a next-generation oral semaglutide formulation that eliminates or significantly reduces the empty-stomach and water restrictions, closing the convenience gap with Foundayo. Combined with oral Wegovy's higher weight-loss efficacy (16.6% vs. 12.4%), the reformulation lets Novo retain or recapture market share. The two companies settle into a stable duopoly similar to the injectable market, differentiated by efficacy versus convenience trade-offs.

4

New entrants from Viking, Structure, or Amgen disrupt the Lilly-Novo duopoly

Discussed by: BioPharma Dive industry analysis, Jefferies biotech research, Endpoints News

Viking Therapeutics, Structure Therapeutics, or Amgen advance their oral or long-acting injectable candidates through Phase 3 trials and reach the market by 2028-2029, breaking the Lilly-Novo duopoly. Viking's dual GLP-1/GIP agonist showed 12.2% weight loss in just 13 weeks of Phase 2 testing, suggesting potentially superior long-term efficacy. One or more of these smaller companies gets acquired by a major pharmaceutical firm seeking obesity market entry, further intensifying competition.

Historical Context

Lipitor and the statin revolution (1996-2012)

1996-2012

What Happened

Pfizer's Lipitor (atorvastatin), approved in 1996, became the best-selling drug in pharmaceutical history by making cholesterol reduction simple — one pill a day. At its peak, Lipitor generated $13 billion annually and was prescribed to over 29 million Americans. It transformed high cholesterol from a condition many people ignored into one routinely treated with a daily pill.

Outcome

Short Term

Lipitor captured over 50% of the statin market within five years, largely by offering superior efficacy and simpler dosing than existing alternatives.

Long Term

Statins became one of the most widely prescribed drug classes in history. When Lipitor lost patent protection in 2011, generic versions drove prices below $10 per month, making treatment nearly universal for at-risk patients.

Why It's Relevant Today

The GLP-1 obesity market is following a similar arc: injectable-first treatments are giving way to oral pills that lower the barrier to entry. If oral GLP-1s achieve statin-like ubiquity, obesity treatment could shift from a specialty intervention to a routine primary-care prescription — with similar implications for public health and pharmaceutical revenue.

Viagra's transformation of erectile dysfunction treatment (1998)

March 1998

What Happened

Pfizer launched Viagra (sildenafil) in March 1998 as the first oral pill for erectile dysfunction, replacing injections, vacuum pumps, and surgical implants. The drug generated $1 billion in sales in its first year. More than the pharmacology, Viagra's significance was in destigmatizing a condition that most men refused to discuss with their doctors — the pill format made treatment feel normal rather than clinical.

Outcome

Short Term

Viagra became the fastest-selling drug launch in history at the time, with 40,000 prescriptions written in its first two weeks.

Long Term

The oral format expanded the treatable market by an order of magnitude. Millions of men who would never have accepted injection-based treatment readily took a pill, establishing the principle that route of administration can be as important as efficacy in determining real-world adoption.

Why It's Relevant Today

Foundayo faces the same dynamic: tens of millions of people who qualify for GLP-1 treatment have avoided it because of needle aversion, injection complexity, or supply shortages. The shift from injection to pill — especially one without food restrictions — could expand the addressable patient population far beyond what clinical efficacy alone would predict.

Gleevec and the targeted therapy pricing precedent (2001)

May 2001

What Happened

Novartis launched Gleevec (imatinib) for chronic myeloid leukemia at $26,400 per year. The drug transformed a fatal cancer into a manageable condition, but its pricing — and subsequent annual increases that pushed costs above $100,000 — ignited a debate about pharmaceutical pricing that continues today. More than 100 oncologists signed an open letter in 2013 calling the pricing unsustainable.

Outcome

Short Term

Gleevec achieved rapid adoption and saved thousands of lives, establishing the modern model of high-priced specialty drugs for chronic conditions.

Long Term

The Gleevec pricing model became the template for specialty drug pricing across therapeutic areas, contributing to the broader pharmaceutical affordability crisis that now shapes how drugs like GLP-1s are priced and covered.

Why It's Relevant Today

Lilly is deliberately breaking from this precedent with Foundayo's $149 self-pay pricing — roughly 85% below injectable GLP-1 list prices. The company is betting that accessibility-first pricing for a condition affecting over 100 million Americans will generate more total revenue than the traditional high-list-price model. If it works, it could reset pricing expectations across the pharmaceutical industry.

Sources

(8)
+2
Eli Lilly Investor Relations BioSpace U.S. Food and Drug Administration STAT News New England Journal of Medicine Eli Lilly CNBC U.S. Food and Drug Administration